A detailed history of Dimensional Fund Advisors LP transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 563,135 shares of PSTX stock, worth $5.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
563,135
Previous 599,812 6.11%
Holding current value
$5.35 Million
Previous $1.75 Million 8.05%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$2.7 - $4.04 $99,027 - $148,175
-36,677 Reduced 6.11%
563,135 $1.61 Million
Q2 2024

Aug 09, 2024

BUY
$2.0 - $3.46 $19,344 - $33,465
9,672 Added 1.64%
599,812 $1.75 Million
Q1 2024

May 10, 2024

BUY
$2.76 - $4.13 $284,111 - $425,138
102,939 Added 21.13%
590,140 $1.88 Million
Q4 2023

Feb 07, 2024

BUY
$1.83 - $3.51 $184,718 - $354,295
100,939 Added 26.13%
487,201 $1.64 Million
Q3 2023

Nov 09, 2023

SELL
$1.62 - $2.79 $509,107 - $876,796
-314,264 Reduced 44.86%
386,262 $919,000
Q2 2023

Aug 09, 2023

SELL
$1.66 - $3.4 $88,974 - $182,236
-53,599 Reduced 7.11%
700,526 $1.23 Million
Q1 2023

May 12, 2023

BUY
$3.08 - $8.73 $1.47 Million - $4.17 Million
477,706 Added 172.82%
754,125 $2.32 Million
Q4 2022

Feb 09, 2023

BUY
$3.33 - $6.38 $517,735 - $991,936
155,476 Added 128.55%
276,419 $1.47 Million
Q3 2022

Nov 10, 2022

SELL
$2.43 - $4.51 $58,536 - $108,641
-24,089 Reduced 16.61%
120,943 $428,000
Q2 2022

Aug 12, 2022

BUY
$1.87 - $5.0 $869 - $2,325
465 Added 0.32%
145,032 $374,000
Q1 2022

May 13, 2022

BUY
$3.22 - $7.04 $152,090 - $332,520
47,233 Added 48.53%
144,567 $648,000
Q4 2021

Feb 09, 2022

BUY
$6.23 - $7.6 $606,390 - $739,738
97,334 New
97,334 $663,000

Others Institutions Holding PSTX

About Poseida Therapeutics, Inc.


  • Ticker PSTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 85,775,600
  • Market Cap $815M
  • Description
  • Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...
More about PSTX
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.